 BEDFORD, Mass., April 06, 2021 GLOBE NEWSWIRE -- Homology Medicines, Inc. Nasdaq: FIXX, a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subject to market and other conditions, 50.0 million of its common stock in an underwritten public offering. Homology expects to grant the underwriter a 30-day option to purchase up to an additional 7.5 million of its common stock. All of the shares in the proposed offering are to be sold by Homology. 